Abstract
Biliary tract cancers (BTCs) are usually diagnosed at an advanced stage and have a dismal prognosis. The treatment of advanced disease is mainly based on systemic chemotherapy, which is demonstrated to improve survival in the first- and second-line setting. Following the results of phase III clinical trials, the combination of cisplatin and gemcitabine is the regimen of choice in the frontline, while 5-fluorouracil plus oxaliplatin is considered the standard after first-line progression in unselected patients. Recent advances in molecular biology have unravelled the molecular heterogeneity of BTCs and identified patient subgroups harbouring unique molecular aberrations such as isocitrate dehydrogenase (IDH) mutations and fibroblast growth factor receptor (FGFR) fusions that can be targeted by specific agents. This knowledge has opened the way to personalised medicine in BTCs. Molecules targeting IDH and FGFR are currently approved for the treatment of advanced, refractory, intrahepatic cholangiocarcinoma. Beyond targeted therapies, novel combinatorial approaches that target the immune microenvironment and the crosstalk between cancer and stroma are being explored based on strong preclinical rationale. This review discusses the current therapeutic opportunities for the management of patients with advanced BTCs and provides an overview of the promising new strategies on the horizon with a particular focus on ongoing clinical trials.
Highlights
Advanced stage is the most common clinical presentation of biliary tract cancers (BTCs)
Thanks to advances in molecular biology, many other therapeutic vulnerabilities have recently been identified both in the tumour and in the surrounding microenvironment, providing a plethora of novel potential strategies to be further investigated for the treatment of BTCs[12]
We aim to offer an overview of the current therapeutic approaches for the management of patients with advanced biliary tract cancers (aBTCs), and to discuss the novel opportunities on the near horizon
Summary
Advanced stage is the most common clinical presentation of biliary tract cancers (BTCs). Advanced disease at presentation or relapse after local treatment, along with the scarce availability of active treatments and the significant chemo-resistance, make BTCs one of the deadliest solid tumours with a global five-year survival rate of 10%[6]. In this scenario, untreated patients have an overall survival (OS) of 3-4 months, while those receiving active treatment can reach up to 18-20 months with two therapeutic lines[7,8,9,10]. Thanks to advances in molecular biology, many other therapeutic vulnerabilities have recently been identified both in the tumour and in the surrounding microenvironment, providing a plethora of novel potential strategies to be further investigated for the treatment of BTCs[12]
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
